Arterra Bioscience S.p.A.

Equities

ABS

IT0005386369

Biotechnology & Medical Research

Market Closed - Borsa Italiana Other stock markets 09:14:59 10/05/2024 pm IST			5-day change	1st Jan Change
1.97 ^EUR	-1.50%		-1.50%	+18.67%

08/05	Mib bearish; focus on quarterlies	AN
07/05	Mib still in the green; Campari drags bullishness	AN

Arterra Bioscience closes 2023 with declining revenues

February 13, 2024 at 05:40 pm IST

(Alliance News) - Arterra Bioscience Spa on Tuesday reported that the board of directors reviewed turnover as of Dec. 31. This amounted to about EUR3.3 million, down 8.6 percent from the same period last year.

Maria Gabriella Colucci - chief executive officer of Arterra Bioscience - commented, "Turnover as of December 31, 2023 is down from about EUR3.6 million to about EUR3.3 million compared to the same period last year, down 8.6 percent."

"The recovery that began in the third quarter and continued throughout the second half of this year makes us optimistic about achieving next year's targets."

Arterra on Tuesday is flat at EUR1.86 per share.

By Maurizio Carta, Alliance News reporter

Comments and questions to redazione@alliancenews.com

Go to the original article.
Legal disclaimer

Latest news about Arterra Bioscience S.p.A.

Mib bearish; focus on quarterlies	08/05	AN
Mib still in the green; Campari drags bullishness	07/05	AN
Indices in green; Iren hurt after Ad shutdown	07/05	AN
Stock markets up; results push UniCredit and Simone	07/05	AN
Mib in green; UniCredit and MPS boost profit	07/05	AN
Mib caresses 34,000; Amplifon bullish	06/05	AN
Arterra Bioscience increases turnover by 26 percent in first quarter	06/05	AN
ITALY GROWTH WINNERS & LOSERS: Askoll EVA rallying; Alfonsino trailing.	24/04	AN
Arterra Bioscience with profit down; board confirms dividend	02/04	AN
Futures down; China sets growth at 5 percent	05/03	AN
Mib slightly down; still strength on Saipem	04/03	AN
Mib opens higher, still good for banks	23/02	AN
Arterra, decree consessione agevolzioni bando Rome Technopole	15/02	AN
Arterra Bioscience closes 2023 with declining revenues	13/02	AN
Banks weigh on Mib in the red	13/02	AN
Futures down slightly; wait for U.S. CPI	13/02	AN
Mib bullish dragged by Saipem and Cucinelli	12/02	AN
Mib bullish; profit taking on MPS	08/02	AN
Arterra Bioscience closes nine months with revenues up	07/11	AN
Arterra Bioscience S.p.A.'s Equity Buyback announced on May 13, 2022, has expired.	28/23/28	CI
Arterra Bioscience buys back own shares for approximately EUR30,000	27/23/27	AN
Arterra Bioscience has purchased more than 11,200 of its own ordinary shares	20/23/20	AN
Arterra Bioscience has purchased more than 26,000 of its own ordinary shares	13/23/13	AN
Arterra Bioscience buys back own shares for more than EUR30,000	06/23/06	AN
Arterra Bioscience reduces profit in half-year; production value down	28/23/28	AN

Chart Arterra Bioscience S.p.A.

Duration

Period

More charts

Company Profile

Arterra Bioscience SpA is an Italy-based biotechnology company. It focuses on research and development of ingredients and natural solutions. By exploiting the potentialities of living organisms such as bacteria, yeasts, plants and animal cells, the Company develops products and processes that serve as enabling technologies and that find horizontal application in various industrial sectors, such as cosmetics, agriculture and nutraceutics. The Companyâs main activities and applications include development of technological platforms, employed in the screening of active compounds for different industrial applications; setting up of new extraction processes, aimed at improving the sustainability and yield of interesting compounds and the production of high-tech raw materials with application in different industrial fields. The Company collaborates with private companies, universities and research institutes all over the world.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ARTERRA BIOSCIENCE S.P.A.	+18.67%	14.35M
MODERNA, INC.	+18.55%	47.02B
LONZA GROUP AG	+48.77%	41.86B
IQVIA HOLDINGS INC.	+0.28%	41.76B
CELLTRION, INC.	-4.27%	28.8B
ICON PUBLIC LIMITED COMPANY	+11.66%	26.05B
ALNYLAM PHARMACEUTICALS, INC.	-22.04%	19.15B
BIO-TECHNE CORPORATION	+4.59%	12.55B
MEDPACE HOLDINGS, INC.	+29.66%	12.34B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.30%	11.82B

Other Biotechnology & Medical Research